TNFAIP2 Promotes HIF1α Transcription and Breast Cancer Angiogenesis by Activating the Rac1-ERK-AP1 Signaling Axis

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Nov 12

PMID 39532855

Authors

Wenlong Ren

Huichun Liang

Jian Sun

Zhuo Cheng

Wenjing Liu

Yingying Wu

Yujie Shi

Zhongmei Zhou

Ceshi Chen

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is well known to play a critical role in breast cancer. We previously reported that TNFAIP2 activates Rac1 to promote triple-negative breast cancer (TNBC) cell proliferation, migration, and chemoresistance. However, the potential contribution of TNFAIP2 to tumor angiogenesis remains unknown. In this study, we demonstrated that TNFAIP2 promotes TNBC angiogenesis by activating the Rac1-ERK-AP1-HIF1α signaling axis. Under hypoxia, TNFAIP2 activates Rac1 and ERK sequentially. Following that, ERK activates the AP-1 (c-Jun/Fra1) transcription factor. By employing chromatin immunoprecipitation and luciferase reporter assays, we showed that AP-1 directly interacts with the HIF1α gene promoter, thereby enhancing its transcription. The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.

References

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

Chen L, Chen C, Liang Y, Tsang N, Chang Y, Hsueh C . A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol. 2010; 24(2):175-84. DOI: 10.1038/modpathol.2010.193. View

Kharman-Biz A, Gao H, Ghiasvand R, Zhao C, Zendehdel K, Dahlman-Wright K . Expression of activator protein-1 (AP-1) family members in breast cancer. BMC Cancer. 2013; 13:441. PMC: 3849565. DOI: 10.1186/1471-2407-13-441. View

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

Fang H, Ren W, Cui Q, Liang H, Yang C, Liu W . Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1. Elife. 2023; 12. PMC: 10547475. DOI: 10.7554/eLife.88483. View

Shu L, Chen A, Li L, Yao L, He Y, Xu J . NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation. Oncogene. 2022; 41(6):907-919. DOI: 10.1038/s41388-021-02142-4. View

Cheng Z, Wang H, Li X, Wu Z, Han Y, Li Y . MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. J Exp Clin Cancer Res. 2015; 34:27. PMC: 4387599. DOI: 10.1186/s13046-015-0142-9. View

Sarma V, Wolf F, Marks R, Shows T, Dixit V . Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. J Immunol. 1992; 148(10):3302-12. View

Ayoub N, Jaradat S, Al-Shami K, Alkhalifa A . Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Front Pharmacol. 2022; 13:838133. PMC: 8913593. DOI: 10.3389/fphar.2022.838133. View

10.

Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O . RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29(10):1252-60. DOI: 10.1200/JCO.2010.28.0982. View

11.

Chen J, Deng S, Zhang Y, Wang C, Hu X, Kong D . Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer. Ann Transl Med. 2021; 9(12):1001. PMC: 8267319. DOI: 10.21037/atm-21-805. View

12.

Teleanu R, Chircov C, Grumezescu A, Teleanu D . Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med. 2020; 9(1). PMC: 7020037. DOI: 10.3390/jcm9010084. View

13.

Davis M, Ha B, Holman E, Halaban R, Schlessinger J, Boggon T . RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc Natl Acad Sci U S A. 2013; 110(3):912-7. PMC: 3549122. DOI: 10.1073/pnas.1220895110. View

14.

Chen W, Hoffmann A, Liu H, Liu X . Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018; 2(1):4. PMC: 5871901. DOI: 10.1038/s41698-018-0047-0. View

15.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis R . Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27(30):4966-72. PMC: 2799052. DOI: 10.1200/JCO.2008.21.6630. View

16.

Kim H, Kim Y, Nam B, Kong H, Kim H, Jin Kim Y . HIF-1alpha expression in response to lipopolysaccaride mediates induction of hepatic inflammatory cytokine TNFalpha. Exp Cell Res. 2007; 313(9):1866-76. DOI: 10.1016/j.yexcr.2007.03.009. View

17.

SALCEDA S, Caro J . Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997; 272(36):22642-7. DOI: 10.1074/jbc.272.36.22642. View

18.

Rajabi M, Mousa S . The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017; 5(2). PMC: 5489820. DOI: 10.3390/biomedicines5020034. View

19.

Kim A, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers D . Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol. 2006; 15(7):538-46. DOI: 10.1111/j.1600-0625.2006.00445.x. View

20.

Jia L, Shi Y, Wen Y, Li W, Feng J, Chen C . The roles of TNFAIP2 in cancers and infectious diseases. J Cell Mol Med. 2018; 22(11):5188-5195. PMC: 6201362. DOI: 10.1111/jcmm.13822. View